Conatus Pharmaceuticals to Present at Stifel 2016 Healthcare Conference
November 09 2016 - 7:30AM
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its
scheduled presentation to provide an overview of the company’s
programs and outlook at the Stifel 2016 Healthcare Conference in
New York at 8:45 a.m. ET on Wednesday, November 16, 2016.
An audio webcast and copy of the presentation will
be available in the Investors section of the company’s website at
www.conatuspharma.com.
About Conatus
PharmaceuticalsConatus is a biotechnology company focused
on the development and commercialization of novel medicines to
treat liver disease. Conatus is developing its lead compound,
emricasan, for the treatment of patients with chronic liver
disease. Emricasan is a first-in-class, orally active pan-caspase
protease inhibitor designed to reduce the activity of enzymes that
mediate inflammation and apoptosis. Conatus believes that by
reducing the activity of these enzymes, emricasan has the potential
to interrupt the disease progression across the spectrum of liver
disease. For additional information, please visit
www.conatuspharma.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical facts
contained in this press release are forward-looking statements,
including statements regarding emricasan’s potential to interrupt
the disease progression across the spectrum of liver
disease. In some cases, you can identify forward-looking
statements by terms such as “may,” “will,” “should,” “expect,”
“plan,” “anticipate,” “could,” “intend,” “target,” “project,”
“contemplates,” “believes,” “estimates,” “predicts,” “potential” or
“continue” or the negative of these terms or other similar
expressions. These forward-looking statements speak only as of
the date of this press release and are subject to a number of
risks, uncertainties and assumptions, including those risks
described in the company’s prior press releases and in the periodic
reports it files with the Securities and Exchange
Commission. The events and circumstances reflected in the
company’s forward-looking statements may not be achieved or occur
and actual results could differ materially from those projected in
the forward-looking statements. Except as required by applicable
law, the company does not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or
otherwise.
MEDIA: David Schull
Russo Partners, LLC
(858) 717-2310
David.Schull@RussoPartnersLLC.com
INVESTORS: Alan Engbring
Conatus Pharmaceuticals Inc.
(858) 376-2637
aengbring@conatuspharma.com
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Apr 2023 to Apr 2024